Medical Condition News

RSS

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

New report reveals potential breakthrough in pterygium treatment

A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Kessler Foundation receives Collaborative MS Research Center Award

Kessler Foundation is the recipient of a MS Research Center Award from the National Multiple Sclerosis Society. John DeLuca, PhD, is principal investigator for the five-year $821,000 grant, which will fund the MS Collaborative Network of New Jersey. The MSCNNJ will bring together the Foundation's experts in mobility and cognitive research to advance understanding of cognitive-motor interaction in MS. Dr. DeLuca is Senior Vice President of Research and Training at the Foundation.

1 Apr 2014

Full-field digital mammography associated with lower recall and biopsy rates, says study

Population-based screening with full-field digital mammography (FFDM) is associated with lower recall and biopsy rates than screen film mammography (SFM), suggesting that FFDM may reduce the number of diagnostic workups and biopsies that do not lead to diagnosis of breast cancer, according to a new study published online in the journal Radiology.

1 Apr 2014

UT Southwestern launches telemedicine program to extend stroke care to patients in rural areas

UT Southwestern Medical Center has launched a state-of-the-art telemedicine program that will extend immediate access to UT Southwestern's nationally recognized stroke care during the crucial time period when treatment is needed for a patient of an ischemic stroke, or clot in one of the brain's blood vessels.

1 Apr 2014

Researchers identify two new genes associated with intellectual disability

Researchers at the Centre for Addiction and Mental Health have discovered two new genes linked to intellectual disability, according to two research studies published concurrently this month in the journals Human Genetics and Human Molecular Genetics.

1 Apr 2014

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness.

1 Apr 2014

Sleep fragmentation, poor sleep quality associated with decline in executive function

A new study of older men found a link between poor sleep quality and the development of cognitive decline over three to four years.

1 Apr 2014

Young adults with cardiac risk factors have worse cognitive function in middle age

Young adults with such cardiac risk factors as high blood pressure and elevated glucose levels have significantly worse cognitive function in middle age, according to a new study by dementia researchers at UC San Francisco.

1 Apr 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Medical Condition News

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

New report reveals potential breakthrough in pterygium treatment

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Kessler Foundation receives Collaborative MS Research Center Award

Full-field digital mammography associated with lower recall and biopsy rates, says study

UT Southwestern launches telemedicine program to extend stroke care to patients in rural areas

Researchers identify two new genes associated with intellectual disability

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Sleep fragmentation, poor sleep quality associated with decline in executive function

Young adults with cardiac risk factors have worse cognitive function in middle age

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News